

JC02 Rec'd PCT/PTC

21 MAR 2005  
PATENTS

#41

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Henning WALCZAK, et al.

U.S. Application No. 10/525,681

U.S. Filing Date: February 23, 2005

Int'l App. No. PCT/EP03/09350

Int'l Filing Date August 23, 2003

For: CAPSASE 10 AS TARGET FOR MONITORING  
AND TREATMENT OF DISEASES

Art Unit: Not yet assigned

Examiner: Not yet assigned

---

INFORMATION DISCLOSURE STATEMENT

---


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of the cited art should be forwarded by the International Bureau, and therefore already at the Examiner's disposal for review.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,


  
William L. Warren  
Reg. No. 36,714.


Date: March 16, 2005

SUTHERLAND, ASBILL & BRENNAN, LLP  
999 Peachtree Street, N.E.  
Atlanta, Georgia 30309-3996  
Tel: (404) 853-8000  
Fax: (404) 853-8806  
Docket No.: 18744-0030

---

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313, on March 16, 2005.

  
William L. Warren - Reg. No. 36,714



#4

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/525,681	
				Filing Date	February 23, 2005	
				First Named Inventor	Henning WALCZAK et al.	
				Art Unit		
				Examiner Name		
Sheet	1	of	1	Attorney Docket Number	18744-0030	
<b>U. S. PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>2</sup> (if known)				
	A1	US-5,786,173	07-28-1998	Emad S. Alnemri et al.		
	A2	US-5,851,815 A	12-22-1998	Emad S. Alnemri et al.		
	A3	US-6,171,821 B1	01-09-2001	Robert G. Korneluk et al.		
	A4	US-6,114,132 A	09-05-2000	Anthony Ford-Hutchinson et al.		
	A5	US				
	A6	US				
	A7	US				
	A8	US				
	A9	US				
	A10	US				
	A11	US				
	A12	US				
	A13	US				
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Patent Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>2</sup> (if known)				
	B1					
	B2					
	B3					
<b>NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the volume (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
	C1	Narita et al.: "Analysis of heat-shock related gene expression in head- and neck cancer using cDNA arrays", Int. J. Radiation Oncology Biol. Phys. vol. 53, no. 1, 2002, pages 190-196, XP001135178				
	C2	Villa Pascal et al.: "Caspases and caspase inhibitors", Trends in Biochemical Sciences, vol. 22, no. 10, 1997, pages 388-393, XP002230757, ISSN: 0968-0004				
	C3	Vincenz C. et al.: "Fas-Associated Death Domain Protein Interleukin-1Beta-Converting Enzyme 2 (FLICE2), an ICE/CED-3 Homologue, is proximally involved in CD95- and P55-Mediated Death Signaling", Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US, vol. 272, no. 10, 7 March 1997, pages 6578-6583, XP002037530, ISSN: 0021-9258				
	C4	Fernandes-Alnemri T. et al.: "In Vitro Activation of CPP32 and MCH3 by MCH4, a Novel Human Apoptotic Cystein Protease Containing Two Fadd-Like Domains" proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, US, vol. 93, no. 15, 23 July 1996, pages 7464-7469, XP000616167, ISSN: 0027-8424				
	C5	Kischkel et al.: "Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8" Journal of Biological Chemistry, vol. 276, no. 49, 2001, pages 46639-46646, XP001135179				
Examiner Signature				Date Considered		

\*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.